lapatinib has been researched along with 2-[[[2-methyl-1-(phenylmethyl)-5-benzimidazolyl]amino]methyl]phenol in 1 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (2-[[[2-methyl-1-(phenylmethyl)-5-benzimidazolyl]amino]methyl]phenol) | Trials (2-[[[2-methyl-1-(phenylmethyl)-5-benzimidazolyl]amino]methyl]phenol) | Recent Studies (post-2010) (2-[[[2-methyl-1-(phenylmethyl)-5-benzimidazolyl]amino]methyl]phenol) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 6 | 0 | 0 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dayam, R; Gundla, R; Kazemi, R; Muttineni, R; Neamati, N; Sanam, R; Sarma, JA | 1 |
1 other study(ies) available for lapatinib and 2-[[[2-methyl-1-(phenylmethyl)-5-benzimidazolyl]amino]methyl]phenol
| Article | Year |
|---|---|
Discovery of novel small-molecule inhibitors of human epidermal growth factor receptor-2: combined ligand and target-based approach.
Topics: Amino Acid Sequence; Aniline Compounds; Antineoplastic Agents; Binding Sites; Breast Neoplasms; Catalytic Domain; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 3-Ring; Humans; Ligands; Models, Molecular; Molecular Sequence Data; Piperazines; Pyrimidines; Quantitative Structure-Activity Relationship; Quinazolines; Quinolines; Receptor, ErbB-2; Small Molecule Libraries | 2008 |